Replies to post #47590 on Biotech Values

[quantumdot]

>>The drug is a neuroprotectant and is not the same as tpa. Tpa removes the clot.<<

Indeed. It may at first glance seem that companies like D-Pharma and Neuren should undertake trials of their neuroprotectants in combo with plasminogen activators.

However, t-PA is the only approved option and given that it is used so infrequently (4-5% of stroke cases) and has such a restrictive efficacy window it would seem it is simply not worth trying to deal with the complexity it would introduce into trials. This particularly so given the risk of SAEs it would introduce.

I suspect that when (if) desmoteplase is approved with its longer therapeutic window and reduced SE profile we may well see some combo studies combining it with the new neuroprotectants (e.g. DP-b99 and NNZ-2566) that are showing such high promise.